GERON CORP (GERN) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:GERN • US3741631036

1.48 USD
+0.01 (+0.68%)
Last: Feb 5, 2026, 10:44 AM
Fundamental Rating

3

GERN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. Both the profitability and financial health of GERN have multiple concerns. GERN shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year GERN has reported negative net income.
  • GERN had a negative operating cash flow in the past year.
  • GERN had negative earnings in each of the past 5 years.
  • In the past 5 years GERN always reported negative operating cash flow.
GERN Yearly Net Income VS EBIT VS OCF VS FCFGERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -14.04%, GERN belongs to the top of the industry, outperforming 80.34% of the companies in the same industry.
  • GERN's Return On Equity of -32.02% is fine compared to the rest of the industry. GERN outperforms 75.00% of its industry peers.
Industry RankSector Rank
ROA -14.04%
ROE -32.02%
ROIC N/A
ROA(3y)-50.19%
ROA(5y)-45.98%
ROE(3y)-104.64%
ROE(5y)-88.33%
ROIC(3y)N/A
ROIC(5y)N/A
GERN Yearly ROA, ROE, ROICGERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Gross Margin of GERN (97.70%) is better than 97.52% of its industry peers.
  • The Profit Margin and Operating Margin are not available for GERN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GERN Yearly Profit, Operating, Gross MarginsGERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • GERN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, GERN has more shares outstanding
  • GERN has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, GERN has a worse debt to assets ratio.
GERN Yearly Shares OutstandingGERN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GERN Yearly Total Debt VS Total AssetsGERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • GERN has an Altman-Z score of -1.87. This is a bad value and indicates that GERN is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -1.87, GERN is in line with its industry, outperforming 52.86% of the companies in the same industry.
  • A Debt/Equity ratio of 0.92 indicates that GERN is somewhat dependend on debt financing.
  • GERN's Debt to Equity ratio of 0.92 is on the low side compared to the rest of the industry. GERN is outperformed by 74.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.92
Debt/FCF N/A
Altman-Z -1.87
ROIC/WACCN/A
WACC8.55%
GERN Yearly LT Debt VS Equity VS FCFGERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

  • A Current Ratio of 5.96 indicates that GERN has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 5.96, GERN is in the better half of the industry, outperforming 61.83% of the companies in the same industry.
  • A Quick Ratio of 4.87 indicates that GERN has no problem at all paying its short term obligations.
  • GERN has a Quick ratio of 4.87. This is comparable to the rest of the industry: GERN outperforms 57.06% of its industry peers.
Industry RankSector Rank
Current Ratio 5.96
Quick Ratio 4.87
GERN Yearly Current Assets VS Current LiabilitesGERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • GERN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.50%, which is quite impressive.
  • Looking at the last year, GERN shows a very strong growth in Revenue. The Revenue has grown by 522.13%.
  • The Revenue has been growing by 178.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)522.13%
Revenue growth 3Y281.2%
Revenue growth 5Y178.45%
Sales Q2Q%67.05%

3.2 Future

  • Based on estimates for the next years, GERN will show a very strong growth in Earnings Per Share. The EPS will grow by 26.85% on average per year.
  • GERN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 58.91% yearly.
EPS Next Y57.19%
EPS Next 2Y35.28%
EPS Next 3Y30.34%
EPS Next 5Y26.85%
Revenue Next Year151.04%
Revenue Next 2Y84.79%
Revenue Next 3Y72.5%
Revenue Next 5Y58.91%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
GERN Yearly Revenue VS EstimatesGERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
GERN Yearly EPS VS EstimatesGERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.2 -0.2 0.4 -0.4

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • GERN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GERN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GERN Price Earnings VS Forward Price EarningsGERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GERN Per share dataGERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 0.3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as GERN's earnings are expected to grow with 30.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.28%
EPS Next 3Y30.34%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • GERN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GERON CORP

NASDAQ:GERN (2/5/2026, 10:44:03 AM)

1.48

+0.01 (+0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)02-24
Inst Owners80.6%
Inst Owner Change-0.33%
Ins Owners0.07%
Ins Owner Change1.33%
Market Cap944.77M
Revenue(TTM)183.40M
Net Income(TTM)-79.64M
Analysts78.46
Price Target3.4 (129.73%)
Short Float %11.1%
Short Ratio7.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.29%
Min EPS beat(2)10.87%
Max EPS beat(2)35.71%
EPS beat(4)4
Avg EPS beat(4)20.57%
Min EPS beat(4)10.87%
Max EPS beat(4)35.71%
EPS beat(8)8
Avg EPS beat(8)20.89%
EPS beat(12)11
Avg EPS beat(12)19.53%
EPS beat(16)13
Avg EPS beat(16)15.92%
Revenue beat(2)1
Avg Revenue beat(2)-4.92%
Min Revenue beat(2)-12.44%
Max Revenue beat(2)2.61%
Revenue beat(4)2
Avg Revenue beat(4)-6.81%
Min Revenue beat(4)-19.48%
Max Revenue beat(4)2.61%
Revenue beat(8)5
Avg Revenue beat(8)159.07%
Revenue beat(12)6
Avg Revenue beat(12)107.74%
Revenue beat(16)9
Avg Revenue beat(16)189.91%
PT rev (1m)0%
PT rev (3m)-8.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.36%
EPS NY rev (1m)0%
EPS NY rev (3m)0.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-17.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.15
P/FCF N/A
P/OCF N/A
P/B 3.8
P/tB 3.8
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.29
BVpS0.39
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.04%
ROE -32.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.7%
FCFM N/A
ROA(3y)-50.19%
ROA(5y)-45.98%
ROE(3y)-104.64%
ROE(5y)-88.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.92
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.95%
Cap/Sales 0.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.96
Quick Ratio 4.87
Altman-Z -1.87
F-Score4
WACC8.55%
ROIC/WACCN/A
Cap/Depr(3y)153.53%
Cap/Depr(5y)161.21%
Cap/Sales(3y)140.92%
Cap/Sales(5y)119.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y57.19%
EPS Next 2Y35.28%
EPS Next 3Y30.34%
EPS Next 5Y26.85%
Revenue 1Y (TTM)522.13%
Revenue growth 3Y281.2%
Revenue growth 5Y178.45%
Sales Q2Q%67.05%
Revenue Next Year151.04%
Revenue Next 2Y84.79%
Revenue Next 3Y72.5%
Revenue Next 5Y58.91%
EBIT growth 1Y69.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.04%
EBIT Next 3Y19.08%
EBIT Next 5YN/A
FCF growth 1Y18.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.91%
OCF growth 3YN/A
OCF growth 5YN/A

GERON CORP / GERN FAQ

Can you provide the ChartMill fundamental rating for GERON CORP?

ChartMill assigns a fundamental rating of 3 / 10 to GERN.


Can you provide the valuation status for GERON CORP?

ChartMill assigns a valuation rating of 1 / 10 to GERON CORP (GERN). This can be considered as Overvalued.


How profitable is GERON CORP (GERN) stock?

GERON CORP (GERN) has a profitability rating of 2 / 10.